Protect Your Manhood, ZERO collaborate to address prostate health

NewsGuard 100/100 Score
ZERO – The End of Prostate Cancer is partnering with Protect Your Manhood, a New Hampshire seacoast based start-up founded by prostatitis survivor and marketing maven Chris Sargent, which offers a culturally relevant resource to promote prostate health.

"Prostate cancer is just as common as breast cancer, but the social stigmas associated with prostate health present barriers that most men simply will not conquer, alone," said Chris Sargent, Founder of Protect Your Manhood. After suffering from prostate issues, Chris began developing best practices and resources that men and their sexual partners can use to improve prostate health and performance. Protect Your Manhood will donate a portion of proceeds to ZERO.

"Protect Your Manhood is a survivors story, passionately shared man to man," said Jamie Bearse, Chief Strategic Officer and Executive Vice President of ZERO - The End of Prostate Cancer. "ZERO is very grateful for Protect Your Manhoodʼs ongoing financial commitment and appreciate their distinctive voice in addressing menʼs prostate health."

Nearly every treatment breakthrough in prostate cancer in the last five years has been made possible, at least in part, by funding secured by ZERO. And every dollar donated to ZERO is leveraged into $250 for research to find a cure for prostate cancer. With support from organizations like Protect Your Manhood, ZERO plans to continue working to end prostate cancer.

Source:

ZERO - The End of Prostate Cancer

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis